Kenneth E. Eheman Jr.
Attorney, Attorney at Wyrick Robbins Yates & Ponton
SEBIO Board of Directors (2017-2019)Southeast Life Sciences Association Board and Executive CommitteeCenter for Entrepreneurial Development, Board of Directors (2011-2017)Co-Chair, CED Biotech Conference 2006, SEBIO Conference 2018Carolina Kickstart External Advisory BoardCoach, UNC Launching the Venture and Research to Revenue CoursesAmerican Bar Association, Private Equity and Venture Capital SectionsNorth Carolina State Bar and New York State Bar
About
Kenneth E. Eheman Jr. focuses his mergers and acquisitions practice on life sciences and information technology. He leads the Life Sciences industry team at Wyrick Robbins Yates & Ponton. His work also includes venture capital financings and strategic partnerships. He graduated cum laude from the University of Pennsylvania Law School. He joined the firm in 1998 after practicing at Skadden, Arps, Slate, Meagher & Flom LLP. He also practiced at Brobeck, Phleger & Harrison, LLP in New York. He represents start-up and emerging growth companies, public companies, and venture capitalists in his corporate and securities practice.
Who is a good fit for Kenneth E. Eheman Jr.
- Life sciences companies seeking counsel on mergers or acquisitions.
- Public companies seeking corporate and securities counsel for an acquisition.
Education and admissions
- Education
- University of North Carolina at Chapel Hill
- University of Pennsylvania Law School
- Bar admissions
- North Carolina
Recognition
- Listed among Business North Carolina Magazine Legal Elite: Business (2022); Corporate Law (2024)
- Listed among The Best Lawyers in America: Biotechnology Law, Corporate Law, Venture Capital Law (2007-2027); Mergers & Acquisitions Law (2014-2027)
- Best Lawyers® Raleigh 2020 “Lawyer of the Year” Biotechnology and Life Sciences Practice
- Best Lawyers® Raleigh 2021 “Lawyer of the Year” Venture Capital Law
- Listed among The Legal 500 United States North Carolina Corporate and M&A Elite City Rankings (2026)
Specialties
Buy-side M&A representationSell-side M&A representationEntity formation and holding structuresLegal due diligenceEscrow and closing services
Representative matters
As described on the firm’s website.
- Represented major investor syndicate in the over $500 million sale of their virtual-first healthcare multi-brand platform portfolio company to a strategic partner. (seller side)
- Represented strategic investor in multiple early-stage equity investments in U.S. and overseas life sciences start-ups aggregating over $300 million in proceeds.
- Served as outside counsel to Oncology focused university spin-out drug development company in $12 million Series A Financing. ($12,000,000)
- Represented strategic investor in $50 million Series B Investment in a genomic engineering company. ($50,000,000)
- Represented acquirer of two early-stage oncology-focused drug development companies for aggregate $150 million plus milestones of up to $500 million. ($150,000,000, buyer side)
- Served as outside counsel to university spin-out genomics therapeutics company in $10 million Series B financing. ($10,000,000)
- Represent a variety of strategic investors in a series of investments in life sciences/agricultural venture capital funds/incubators/accelerators aggregating more than $400 million in capital commitments.
- Represented strategic investors and life sciences companies in multiple option to acquire transactions.
- Served as outside counsel to drug development company from formation through $50 million private placements, IPO, follow on offerings, and ultimate sale for $300 million. ($300,000,000)
- Served as outside counsel to early-stage university spin-out oncology company in $5,000,000 seed financing ($5,000,000)
Deal profile
- Typical deal size
- Any deal size
- Remote work
- In-person / regional